Cargando…

Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis

Based on a large cohort of clinical studies involving a total of 8024 patients and reporting the effects of HER4 on breast cancer prognosis, we conducted the first meta-analysis and review of this type. We identified 26 studies published between 1985 and 2016 and assessed the prognostic value of HER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jue, Yin, Jun, Yang, Qing, Ding, Feng, Chen, Xiao, Li, Bingjie, Tian, Xingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363541/ https://www.ncbi.nlm.nih.gov/pubmed/27736797 http://dx.doi.org/10.18632/oncotarget.12485

Ejemplares similares

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis
por: Tian, Wei-Jie, et al.
Publicado: (2016)

Toll-Like Receptor 4 as a Favorable Prognostic Marker in Bladder Cancer: A Multi-Omics Analysis
por: Lu, Jun-Lin, et al.
Publicado: (2021)

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer: HER1–4 protein expression and prognosis in pancreatic cancer
por: Li, Qin, et al.
Publicado: (2016)

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer
por: Chan, David S. Y., et al.
Publicado: (2012)

FOXP4‐AS1 is a favorable prognostic-related enhancer RNA in ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells
por: Kim, Yeong Hoon, et al.
Publicado: (2017)

The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis
por: Zhang, Chi, et al.
Publicado: (2019)

Upregulation of epidermal growth factor receptor 4 in oral leukoplakia
por: Kobayashi, Hiroshi, et al.
Publicado: (2013)

Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children
por: Li, Baihong, et al.
Publicado: (2018)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer.
por: Kaklamanis, L., et al.
Publicado: (1992)

Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
por: Tovey, Sian M, et al.
Publicado: (2004)

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
por: Siddiqui, Mohammad R., et al.
Publicado: (2019)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Tumour Cannabinoid CB(1) Receptor and Phosphorylated Epidermal Growth Factor Receptor Expression Are Additive Prognostic Markers for Prostate Cancer
por: Fowler, Christopher J., et al.
Publicado: (2010)

Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients’ Clinical Features
por: Li, Wei, et al.
Publicado: (2018)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor
por: Kim, Hyeryeong, et al.
Publicado: (2017)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
por: Laux, I, et al.
Publicado: (2006)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2019)

PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland
por: Yoshimura, Takuya, et al.
Publicado: (2021)

Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer
por: Zhang, Yongjun, et al.
Publicado: (2015)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

Prognostic significance of epidermal growth factor receptor expression in glioma patients
por: Li, Junhong, et al.
Publicado: (2018)

Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma
por: Wang, Jinn-Li, et al.
Publicado: (2018)

The expression and prognostic value of the epidermal growth factor receptor family in glioma
por: Xu, Bin, et al.
Publicado: (2021)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
por: Mishra, Anjali, et al.
Publicado: (2020)

Deregulation of the pRb-E2F4 axis alters epidermal homeostasis and favors tumor development
por: Costa, Clotilde, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rblihq7uje3c0kiq0t2k4ophe1